MannKind To Pay $23M In Investor Suit Over Diabetes Drug
A California judge on Monday preliminarily approved MannKind Corp.'s $23 million securities class action settlement with shareholders who claim the pharmaceutical company misled them about the regulatory approval prospects of its...To view the full article, register now.
Already a subscriber? Click here to view full article